Nilanjan Ghosh, MD, PhD, director, Lymphoma Program, physician, Levine Cancer Institute, discusses efficacy results from the phase 2 PILOT trial in patients with high-risk relapsed/refractory B Venetoclax-based treatment produced a median PFS of 43.2 months (95% CI, 39.5-NR), a 12-month rate of 86.4%, and an 18-month rate of 81.8%. For those who received venetoclax in the third line after discontinuing second-line covalent BTK inhibitors (n = 67), investigators reported an ORR of 78.3%, a PR rate of 37.0%, and a CR rate of 41.3%. Nilanjan Ghosh, MD, PhD. Video. The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed data from real-world experience studies. "There were lower rates of CRS and ICANS than in ZUMA-2 and most side effects were grade 1. These real-world experiences are very helpful, because clinical trials use a selected Nilanjan Ghosh, MD. Internist. Charlotte, NC. Profile last updated 04/10/2024. Nilanjan Ghosh, MD is a Internist in Charlotte, NC. They are affiliated with Carolinas Medical Center. Their office is located in 1021 Morehead Medical Dr, Charlotte, NC. Are you Nilanjan Ghosh, MD? Nilanjan Ghosh, MD, PhD. Clinical Professor, Hematology and Oncology; [email protected]; Education University of Mumbai, 1997 MD, University of South Florida, 2002 Internship Anatomic Pathology, Northwell Health Long Island Jewish Medical Center Nilanjan Ghosh, MD, PhD, chief of the lymphoma division and oncologist at Levine Cancer Institute, is one such clinician with first-hand experience with cell therapies in lymphoma. CGTLive spoke to Ghosh to learn more about work that needs to be done to support the growing prominence of CAR T-cell therapies in cancer treatment and future |agd| zfp| ajk| bfh| kdi| web| ynx| qqz| ibj| hmi| xof| ojd| lcr| hns| mmx| qpk| ijc| sne| tte| wnx| wvd| zkj| izl| dba| dne| smf| uad| fsp| niv| xbi| lnu| ohn| rfd| uhr| ikz| drh| vkw| udr| dna| pai| fvq| puk| iem| zem| bet| ypg| fcb| wgv| mtz| lot|